Company intelligence / Profile preview

Run Ridge

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

Ridge Biotechnologies leverages proprietary ML models and high-throughput, cell-free datasets to accelerate precision enzyme and drug design, aiming for site-specific bioconjugation, safer payload delivery, and new catalytic mechanisms for challenging drug targets. Initial products (NativeLink, ProTrigger) support development of next-generation ADCs and enzyme-based therapies, and a discovery collaboration with a leading ADC biotech is underway. Ridge Bio is preclinical and not yet reporting clinical results.[1][2][3][4]

Modalities: Enzyme-based therapeuticsAntibody-drug conjugateCAR-T cell therapySmall moleculeNucleic acid deliveryRadiopharmaceuticalBiologicPeptides
Industry: Biotech

Partnerships

Undisclosed leading ADC-focused biotech companyBiopharma and CDMO collaborations

Beyond the preview

Go deeper on Run Ridge.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Run Ridge.

Explore the full profile